åêðáéäåõóçó γ.ν.α.

438 Τι νεότερο στη Χαπ: Διάγνωση και θεραπεία
56.
16. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and
fluticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med. 2007;356(8):775-
89.
17. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium
for stable chronic obstructive pulmonary disease: A
meta-analysis.Thorax. 2006;61(10):854-62.
18. Perng DW, Wu CC, Su KC, et al. Additive benefits of
tiotropium in COPD patients treated with long-acting
beta agonists and corticosteroids. Respirology.
2006;11(5):598-602.
19. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium
in combination with placebo, salmeterol, or
fluticasone-salmeterol for treatment of chronic obstructive
pulmonary disease: a randomized trial. Ann Intern
Med. 2007; 146(8):545-55.
20. Fan Chung K. Phosphodiesterase inhibitors in airways
disease.Eur J Pharmacol. 2006; 533(1-3):110-7.
21. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect
of 1-year treatment with roflumilast in severe chronic
obstructive pulmonary disease. Am J Respir Crit Care
Med. 2007; 176(2):154-61.
22. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial
agonists for smoking cessation. Cochrane Database Syst
Rev. 2008;(3).
xxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxx